Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Bhutan.
Press releases published on October 15, 2025
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq …
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext Compartiment : B Code ISIN : …
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomes More than 40 abstracts …
Vara erhält CE-Zertifizierung als einzige KI für eine unabhängige Zweitbefundung in der Mammographie und expandiert in Europa
BERLIN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vara gab heute eine neue CE-Zertifizierung bekannt – die einzige künstliche Intelligenz (KI) auf dem Markt, welche als unabhängige Zweitbefundung sowohl im Screening als auch in der Diagnostik eingesetzt werden …
Vara earns CE mark as the only AI authorized for an independent second read in mammography, and expands in Europe
BERLIN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vara announced today it received a new CE certificate for its new breast-imaging AI – the only on the market allowed to operate as an independent second reader for both screening and diagnostic use. It marks the …
EyePoint Announces Pricing of Public Offering
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …